论文信息 - Molecular remission of Philadelphia/bcr‐abl‐positive acute myeloid leukaemia after treatment with anti‐CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA‐676)

Molecular remission of Philadelphia/bcr‐abl‐positive acute myeloid leukaemia after treatment with anti‐CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA‐676)

The anti‐CD33 monoclonal antibody linked to NAc‐gamma calicheamicin gemtuzumab ozogamicin (CMA‐676) was used to treat a patient with Philadelphia/bcr‐abl‐positive acute myeloid leukaemia. We report a morphological and cytogenetic complete remission after treatment with two doses of gemtuzumab ozogamicin as a single agent. Using real‐time polymerase chain reaction (PCR), gemtuzumab ozogamicin treatment resulted in a 3‐log tumour mass reduction in bone marrow.

[1] D. Scheinberg,et al. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2] I. Bernstein,et al. CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate , 2017 .

[3] Schaap,et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real‐time quantitative RT‐PCR , 1998, British journal of haematology.

[4] D. Scheinberg,et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5] T. Miyazaki,et al. Establishment and characterization of a cell line, TOM-1, derived from a patient with Philadelphia chromosome-positive acute lymphocytic leukemia. , 1987, Blood.